%PDF-1.4
%
64 0 obj
<>
endobj
61 0 obj
<>
endobj
106 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-03-01T11:09:54Z
2024-03-28T18:03:21-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T18:03:21-07:00
application/pdf
Heather
2004-327.mar
uuid:18c87290-1dd2-11b2-0a00-e109275dc400
uuid:18c87293-1dd2-11b2-0a00-810000000000
endstream
endobj
50 0 obj
<>
endobj
51 0 obj
<>
endobj
65 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
24 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
132 0 obj
[136 0 R]
endobj
133 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 10 0 0 10 53.468 735.6616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 60.468 725.6616 Tm
[(1.)-875.1 (Felson DT)73.9 (. Epidemiology of osteoarthritis. In: Brandt KF)79.7 (, Doherty)]TJ
1.675 -1.25 Td
(M, Lohmander LJ, editors. Osteoarthritis. Oxford: Oxford)Tj
0 -1.25 TD
(University Press; 1998:13-22.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Ledingham J, Dawson S, Preston B, Milligan G, Doherty M.)]TJ
1.675 -1.25 Td
(Radiographic progression of hospital referred osteoarthritis of the)Tj
0 Tc T*
[(hip. )54.9 (Ann Rheum Dis 1993;52:263-7.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Ravaud P)110.7 (, Giraudeau B, )54.8 (Auleley G-R, et al. )17.7 (V)110.8 (ariability in knee )]TJ
1.675 -1.25 Td
(radiographing: implication for definition of radiological progression)Tj
T*
[(in medial knee osteoarthritis. )54.8 (Ann Rheum Dis 1998;57:624-9.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Garnero P)110.7 (, Rousseau J-C, Delmas P)110.7 (. Molecular basis and clinical)]TJ
1.675 -1.25 Td
(use of biochemical markers of bone, cartilage and synovium in)Tj
T*
[(joint diseases. )54.8 (Arthritis Rheum 2000;43:953-61.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Otterness IG, Swindell )54.8 (AC, Zimmerer RO, Poole )54.8 (AR, Ionescu M,)]TJ
1.675 -1.25 Td
[(W)79.9 (einer E. )54.8 (An analysis of 14 molecular markers for monitoring)]TJ
T*
(osteoarthritis: segregation of the markers into clusters and )Tj
T*
(distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage)Tj
0 Tc 0 Tw T*
(2000;8:180-5.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(6.)-875.1 (Otterness IG, )17.7 (W)79.9 (einer E, Swindell )54.8 (AC, Zimmerer RO, Ionescu M,)]TJ
1.675 -1.25 Td
[(Poole )54.8 (AR. )54.8 (An analysis of 14 molecular markers for monitoring)]TJ
T*
(osteoarthritis: Relationship of the markers to clinical end-points.)Tj
T*
(Osteoarthritis Cartilage 2001;9:224-31.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Altman R, )54.8 (Alarcon G, )54.8 (Appelrouth D, et al. )17.7 (The )54.8 (American College)]TJ
1.675 -1.25 Td
(of Rheumatology criteria for the classification and reporting of)Tj
T*
[(osteoarthritis of the hip. )54.8 (Arthritis Rheum 1991;34:505-14.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Dougados M, Nguyen M, Berdah L, Mazi\217res B, )17.7 (V)59.8 (ignon E,)]TJ
1.675 -1.25 Td
[(Lequesne M. Evaluation of the structure-modifying ef)17.7 (fects of )]TJ
T*
[(diacerein in hip osteoarthritis. )54.8 (Arthritis Rheum 2002;44:2539-47.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Lequesne M, Mery C, Samson M, Gerard P)110.7 (. Indexes of severity for)]TJ
-0.0051 Tc 1.675 -1.25 Td
(osteoarthritis of the hip and knee. Scand J Rheumatol 1987;65:85-9.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (Lequesne M. Quantitative measurements of joint space during )]TJ
2.175 -1.25 Td
[(progression of osteoarthritis: \322chondrometry)64.8 (.\323 In: Kuettner KE,)]TJ
T*
[(Goldber)17.7 (g )17.7 (VM, editors. Osteoarthritis disorders. Rosemont:)]TJ
T*
[(American )54.8 (Academy of Orthopedic Sur)17.7 (geons; 1995:427-44.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Auleley GR, Rousselin B, )54.8 (A)91.8 (yral X, Edouard-No\221l R, Dougados M,)]TJ
2.1381 -1.25 Td
[(Ravaud P)110.7 (. Osteoarthritis of the hip: agreement between joint space)]TJ
T*
(width measurements on standing and supine conventional )Tj
0 Tc T*
[(radiographs. )54.9 (Ann Rheum Dis 1998;57:517-23.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact)]TJ
2.175 -1.25 Td
(amino-terminal propeptide of human type I procollagen. Clin Chem)Tj
0 Tc 0 Tw T*
(1996;42:947-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Garnero P)110.7 (, Delmas PD. Evaluation of a fully automated assay for)]TJ
2.175 -1.25 Td
(serum procollagen type I-N propeptide in osteoporosis. J Bone)Tj
T*
(Miner Res 2002;17 Suppl 1:S316.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Risteli J, Niemi S, )17.7 (T)35 (rivedi P)110.7 (, Maentausta O, Mowat )54.8 (AP)110.8 (, Risteli L.)]TJ
2.175 -1.25 Td
(Rapid equilibrium radioimmunoassay for amino-terminal )Tj
T*
(propeptide of human type III procollagen. Clin Chem )Tj
0 Tc 0 Tw T*
(1988;34:715-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Saxne )17.7 (T)74 (, Lindell M, Mansson B, Petersson IF)79.7 (, Heinegard D.)]TJ
2.175 -1.25 Td
(Inflammation is a feature of the disease process in early knee joint)Tj
T*
(osteoarthritis. Rheumatology Oxford 2003;42:903-4.)Tj
-2.175 -1.25 Td
[(16.)-875.1 (Garnero P)110.7 (, Piperno M, Gineyts E, Christgau S, Delmas PD, )17.7 (V)59.8 (ignon)]TJ
2.175 -1.25 Td
(E. Cross-sectional evaluation of biochemical markers of bone, )Tj
T*
(cartilage and synovial tissue metabolism in patients with knee)Tj
T*
[(osteoarthritis: relations with disease activity and joint damage. )54.8 (Ann)]TJ
T*
(Rheum Dis 2001;60:619-26.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Johansen JS, Jensen HS, Price P)91.7 (A. )54.8 (A)-220.1 (new biochemical marker for)]TJ
2.175 -1.25 Td
[(joint injury)64.8 (. )54.8 (Analysis of )36.8 (YKL-40 in serum and synovial fluid. Br )]TJ
T*
(J Rheumatol 1993;32:949-55.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Zhang J, Fujimoto N, Iwata K, Sakai )17.7 (T)74 (, Okada )36.8 (Y)128.9 (, Hayakawa )17.7 (T)74 (.)-0.1 ( )54.8 (A)]TJ
2.175 -1.25 Td
(one-step sandwich enzyme immunoassay for human matrix )Tj
T*
(metalloproteinase 1 \(interstitial collagenase\) using monoclonal )Tj
T*
[(antibodies. Clin Chim )54.8 (Acta 1993;219:1-14.)]TJ
30.825 77.671 Td
[(19.)-875.1 (Obata K, Iwata K, Okada )36.8 (Y)128.9 (, et al. )54.8 (A)-220.1 (one-step sandwich enzyme)]TJ
2.175 -1.25 Td
(immunoassay for human matrix metalloproteinase 3 \(stromelysin-1\))Tj
T*
[(using monoclonal antibodies. Clin Chim )54.8 (Acta 1992;21)36.8 (1:59-72.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Bonde M, Qvist P)110.7 (, Fledelius C, Riis BJ, Christiansen C.)]TJ
2.175 -1.25 Td
(Immunoassay for quantifying type I collagen degradation products)Tj
T*
(in urine evaluated. Clin Chem 1994;40:2022-5.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Christgau S, Garnero P)110.7 (, Fledelius C, et al. Collagen type II )]TJ
2.175 -1.25 Td
(C-telopeptide fragments as an index of cartilage degradation. Bone)Tj
0 Tc 0 Tw T*
(2001;29:209-15.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875.1 (Conrozier )17.7 (T)74 (, Carlier MC, Mathieu P)110.7 (, et al. Serum levels of )36.8 (YKL-40)]TJ
2.175 -1.25 Td
(and C-reactive protein in patients with hip osteoarthritis and)Tj
T*
[(healthy subjects: a cross sectional study)64.8 (. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:828-31.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(23.)-875.1 (V)128.9 (os K, Steenbakkers P)110.7 (, Miltenbur)17.7 (g )54.8 (AM, et al. Raised human )]TJ
2.175 -1.25 Td
(cartilage glycoprotein-39 plasma levels in patients with rheumatoid)Tj
T*
[(arthritis and other inflammatory conditions. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:544-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(24.)-875.1 (Koutroubakis IC, Petinaki E, Dimoulios P)110.7 (, et al. Increased serum)]TJ
2.175 -1.25 Td
[(levels of )36.8 (YKL-40 in patients with inflammatory bowel disease. Int )]TJ
T*
(J Colorectal Dis 2003;18:254-9.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Hedhom E, )54.8 (Antonsson P)110.7 (, Hjerpe )54.8 (A, et al. Cartilage matrix proteins:)]TJ
2.175 -1.25 Td
(an acidic oligomeric protein \(COMP\) detected only in cartilage.)Tj
0 Tc 0.275 -1.25 Td
(J Biol Chem 1992;267:6132-6.)Tj
-0.00011 Tc -2.45 -1.25 Td
[(26.)-875.1 (V)59.8 (ilim )17.7 (V)128.9 (,)-0.1 ( )17.7 (V)110.8 (ytasek R, Olejarova M, et al. Serum cartilage oligomeric)]TJ
2.175 -1.25 Td
(matrix protein reflects the presence of clinically diagnosed )Tj
T*
(synovitis in patients with knee osteoarthritis. Osteoarthritis)Tj
T*
(Cartilage 2001;9:612-8.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Poole R. Can serum biomarker assays measure the progression of)]TJ
2.175 -1.25 Td
[(cartilage degeneration in osteoarthritis? )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:2549-52.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(28.)-875.1 (Garnero P)110.7 (, Delmas PD. Biomarkers in osteoarthritis. Curr Opin)]TJ
2.175 -1.25 Td
(Rheumatol 2003;15:641-6.)Tj
-2.175 -1.25 Td
[(29.)-875.1 (Altman RD, Lozada CJ. Osteoarthritis and related disorders:)]TJ
2.175 -1.25 Td
[(Clinical features. In: Hochber)17.7 (g MC, Silman )54.8 (AJ, )17.7 (W)79.9 (einblatt ME,)]TJ
T*
[(W)79.9 (eisman MH, editors. Rheumatology)64.8 (. 3rd ed. Edinbur)17.7 (gh: Mosby;)]TJ
0 Tc 0 Tw T*
(2001:1793-800.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Pham )17.7 (T)74 (, van der Heidje D, )54.8 (Altman R, et al. OMERACT)91.7 (-OARSI)]TJ
2.175 -1.25 Td
(Initiative: Osteoarthritis Research Society International set of)Tj
T*
(responder criteria for osteoarthritis clinical trials revisited.)Tj
T*
(Osteoarthritis Cartilage 2004;12:389-99.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Mouritzen U, Christgau S, Lehman H-J, et al. Cartilage turnover)]TJ
2.175 -1.25 Td
(assessed with a newly developed assay measuring collagen type II)Tj
T*
(degradation products: influence of age, sex, menopause, hormone)Tj
T*
[(replacement therapy)64.8 (, and body mass index. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2003;62:332-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Dragomir )54.8 (AD, Kraus )17.7 (VB, Renner JB, et al. Serum cartilage)]TJ
2.175 -1.25 Td
(oligomeric matrix protein and clinical signs and symptoms of )Tj
T*
[(pre-radiographic hip and knee pathology)64.8 (. Osteoarthritis Cartilage)]TJ
0 Tc 0 Tw T*
(2002;10:687-91.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875.1 (Garnero P)110.7 (,)-0.1 ( )54.8 (A)91.8 (yral X, Rousseau JC, et al. Uncoupling of )17.7 (T)69.9 (ype II )]TJ
2.175 -1.25 Td
(collagen synthesis and degradation predicts progression of joint)Tj
T*
[(damage in patients with knee osteoarthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;44:2613-24.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(34.)-875.1 (Garnero P)110.7 (, Conrozier )17.7 (T)74 (, Christgau S, Mathieu P)110.7 (, Delmas PD,)]TJ
2.175 -1.25 Td
[(V)59.8 (ignon E. Urinary type II collagen C-telopeptide levels are)]TJ
T*
(increased in patients with a rapidly destructive hip osteoarthritis.)Tj
0 Tc T*
(Ann Rheum Dis 2003;62:939-43.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (Dougados M. Structural progression is also driven by clinical)]TJ
2.175 -1.25 Td
[(symptoms in patients with osteoarthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2004;50:1360-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Garnero P)110.7 (, Sornay-Rendu E, )54.8 (Arlot ME, Christiansen C, Delmas PD.)]TJ
2.175 -1.25 Td
(Association between spine disc degeneration and type II collagen)Tj
T*
[(degradation in postmenopausal women: )17.7 (The OFEL)99.8 (Y)-238.2 (Study)64.8 (.)]TJ
T*
(Arthritis Rheum 2004;50:3137-44.)Tj
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
0 Tc 0 Tw 8 0 0 8 545.468 56.4344 Tm
(703)Tj
ET
0 0 0 0 k
53.532 70.404 203 -16.416 re
f*
BT
0 0 0 1 k
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.7227 Tm
[(Garner)36.8 (o, et al: Molecular markers and hip OA)]TJ
ET
0 0 0 0 k
/GS0 gs
103.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
44 0 obj
<>stream
8;Z\6>B8aX%-.:>aQmZO(*8\d>>cgj]2Q,$8K4+k5S-WOn+i#>[.>'K^otiJhpE*n
]0?8l55A`KqgSKmF1k<]0%?N3n.P1e=.foCa'1bPk4i!Eis>2U[#;1\/?XIk[[T7D
QthI%5[dAV&>Gm&"k'qB+WtndQ5dEX/_J]?7Kb?_U)&KI)l,2-D1iuF`a0/8p*`gE
pY0"mpjr,9L_7p?iHB1ZetGL$e?kubK93thi?(F\G1X"ee#$g&o/cU_)H$QTTG#La
RE/n&-i'QX%0ocFM2F;8Dm64a;:nmMi6sMG0c`g*?,Aa;?'[.+-+sc/)$u`J-^584
E0HEd`)C'-o!japM>N.ufO,tkk\tTV%@b"JFsq9"TcS0W^*sChkea%L2s"_#8Tgd58kl.C
d%d0^;Ii<3m[DS$@&C!B>,1BX_"6#Z'[Sh<"M)?&1tC[Oi,6?R0^0I@I-mA#]U#AD
7E^ffb:7D?'(/7If,FKjp1F@$a9OYTg\%D:??]E#E<7YWJ>1I1\K`a;K^F`^\1ct/
N!o7&&%3OXG6/7%Jbq;el2?4QmUZ\hJjn/aQOO[@nC!#WJ<53>E\lMf)j%OPNpeOO
^\2B?CWqr9Dh;Fpd,CEJ3lW&a6&!3UJ(ckSU__9/?((P/#G17U'7C_]UF-Ps1s7WOVs9Emi;:AdNW3fnJ'Z0]
T)epm)7g4~>
endstream
endobj
48 0 obj
[/Indexed/DeviceRGB 255 47 0 R]
endobj
47 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
79 0 obj
<>
endobj
77 0 obj
<>
endobj
71 0 obj
<>
endobj
91 0 obj
<>
endobj
111 0 obj
<>
endobj
70 0 obj
<>
endobj
81 0 obj
<>stream
H|TyPWapiۈkXE1ъ$ F.eADVp="W,ijD]X Ah6-5İU {;҃[rޛ=8(MD4KV븀H6^U&FG-8X.p& o*T:N%jQj64ќzNTTNw8BR)ho_پ>&&0cͳVKMvX6aC6aB11c#.rDu--,>vs#L )QKNXY=vNmBmqS#yuػkZ͍D^B1+ʚ:N;tBN]Rh.'NqÊtNtH3&aXol~YoJM#ڃwE7*37?͖l}}Lb]Cemu9sLID유:TBӹ
S=ӢO㻾1t)*Luӷ71UшtU)q4PQᢃ^uCC